Stempeutics strives towards building strong IP portfolio and is proactively engaged in extensive research in the area
of stem cell technology and its application. As on date Stempeutics has filed 68 patents covering three products and
across the globe.
Stempeutics has entered into strategic alliance with Cipla in 2009 for marketing its products. Cipla holds 49% equity in Stempeutics. Cipla extends technical support for production and handles "go-to-market" activities of the product being developed by Stempeutics.